Shteinberg Michal, Elborn J Stuart
Pulmonology and CF Center, Carmel Medical Center, and the Rappaport Faculty of Medicine, Haifa, Israel,
Adv Ther. 2015 Jan;32(1):1-9. doi: 10.1007/s12325-015-0179-3. Epub 2015 Jan 27.
Chronic infection with Pseudomonas aeruginosa is associated with poor outcomes in patients with cystic fibrosis (CF). It leads to a reduced quality of life, acceleration of the decline in lung function, and increased frequency and severity of pulmonary exacerbations. Tobramycin, administered by inhalation as a long-term therapy, decreases bacterial density in airways, reduces exacerbation frequency, and improves quality of life and lung function in patients with chronic P. aeruginosa infection. In the last decade, tobramycin inhalation has become an important contributor to CF treatment as a means to control chronic infection and as a first-line treatment for the eradication of early acquisition of P. aeruginosa. Recently, a dry powder inhalation (DPI) form of tobramycin has become available, which is more convenient for administration and has comparable efficacy to the tobramycin solution. This DPI, the Podhaler™ (Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA), requires less time for treatment delivery and is more portable than a nebulizer, and so is a welcome additional therapeutic option for many patients.
铜绿假单胞菌的慢性感染与囊性纤维化（CF）患者的不良预后相关。它会导致生活质量下降、肺功能下降加速，以及肺部急性加重的频率和严重程度增加。妥布霉素作为长期吸入治疗药物，可降低气道中的细菌密度，减少急性加重频率，并改善慢性铜绿假单胞菌感染患者的生活质量和肺功能。在过去十年中，吸入妥布霉素已成为CF治疗的重要手段，可用于控制慢性感染，并作为根除早期感染铜绿假单胞菌的一线治疗方法。最近，一种干粉吸入（DPI）形式的妥布霉素已上市，其给药更方便，疗效与妥布霉素溶液相当。这种DPI，即Podhaler™（美国新泽西州东哈嫩的诺华制药公司），给药所需时间更少，比雾化器更便于携带，因此是许多患者欢迎的额外治疗选择。
